# A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

> **NCT07543380** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 130 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** RSVpreF

## Key facts

- **NCT ID:** NCT07543380
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-11
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543380, "A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07543380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*